Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
CLINICAL TRIAL
FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
THERAPEUTICS
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
22
12
2022
received:
10
08
2022
accepted:
28
12
2022
pubmed:
31
12
2022
medline:
21
3
2023
entrez:
30
12
2022
Statut:
ppublish
Résumé
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, severely disabling genetic disorder of progressive heterotopic ossification (HO). The single-arm, open-label, phase 3 MOVE trial (NCT03312634) assessed efficacy and safety of palovarotene, a selective retinoic acid receptor gamma agonist, in patients with FOP. Findings were compared with FOP natural history study (NHS; NCT02322255) participants untreated beyond standard of care. Patients aged ≥4 years received palovarotene once daily (chronic: 5 mg; flare-up: 20 mg for 4 weeks, then 10 mg for ≥8 weeks; weight-adjusted if skeletally immature). The primary endpoint was annualized change in new HO volume versus NHS participants (by low-dose whole-body computed tomography [WBCT]), analyzed using a Bayesian compound Poisson model (BcPM) with square-root transformation. Twelve-month interim analyses met futility criteria; dosing was paused. An independent Data Monitoring Committee recommended trial continuation. Post hoc 18-month interim analyses utilized BcPM with square-root transformation and HO data collapsed to equalize MOVE and NHS visit schedules, BcPM without transformation, and weighted linear mixed-effects (wLME) models, alongside prespecified analysis. Safety was assessed throughout. Eighteen-month interim analyses included 97 MOVE and 101 NHS individuals with post-baseline WBCT. BcPM analyses without transformation showed 99.4% probability of any reduction in new HO with palovarotene versus NHS participants (with transformation: 65.4%). Mean annualized new HO volume was 60% lower in MOVE versus the NHS. wLME results were similar (54% reduction fitted; nominal p = 0.039). All palovarotene-treated patients reported ≥1 adverse event (AE); 97.0% reported ≥1 retinoid-associated AE; 29.3% reported ≥1 serious AE, including premature physeal closure (PPC)/epiphyseal disorder in 21/57 (36.8%) patients aged <14 years. Post hoc computational analyses using WBCT showed decreased vertebral bone mineral density, content, and strength, and increased vertebral fracture risk in palovarotene-treated patients. Thus, post hoc analyses showed evidence for efficacy of palovarotene in reducing new HO in FOP, but high risk of PPC in skeletally immature patients. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Substances chimiques
Palovarotene
28K6I5M16G
Pyrazoles
0
Banques de données
ClinicalTrials.gov
['NCT03312634', 'NCT02322255']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-394Subventions
Organisme : Clementia Pharmaceuticals Inc.
Informations de copyright
© 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Références
Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38:525-527.
Liljesthröm M, Pignolo RJ, Kaplan FS. Epidemiology of the global fibrodysplasia ossificans progressiva (FOP) community. J Rare Dis Res Treat. 2020;5:31-36.
Shore EM, Kaplan FS. Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol. 2010;6:518-527.
Zhang W, Zhang K, Song L, et al. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013;57:386-391.
Shen Q, Little SC, Xu M, et al. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest. 2009;119:3462-3472.
Di Rocco M, Baujat G, Bertamino M, et al. International physician survey on management of FOP: a modified Delphi study. Orphanet J Rare Dis. 2017;12:110.
Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013;10(Suppl 2):437-448.
Pignolo RJ, Bedford-Gay C, Liljesthröm M, et al. The natural history of flare-ups in fibrodysplasia ossificans progressiva (FOP): a comprehensive global assessment. J Bone Miner Res. 2016;31:650-656.
Kaplan FS, Pignolo RJ, Al Mukaddam M, et al. Genetic disorders of heterotopic ossification: fibrodysplasia ossificans progressiva and progressive osseous heteroplasia. In Bilezikian J, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 9th ed. Washington, DC: The American Society for Bone and Mineral Research; 2019 pp 865-870.
Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011;6:80.
Kaplan FS, Zasloff MA, Kitterman JA, et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010;92:686-691.
Pignolo RJ, Cheung K, Kile S, et al. Self-reported baseline phenotypes from the International Fibrodysplasia Ossificans Progressiva (FOP) Association Global Registry. Bone. 2020;134:115274.
Connor JM, Evans DA. Genetic aspects of fibrodysplasia ossificans progressiva. J Med Genet. 1982;19:35-39.
Nakahara Y, Kitoh H, Nakashima Y, et al. Longitudinal study of the activities of daily living and quality of life in Japanese patients with fibrodysplasia ossificans progressiva. Disabil Rehabil. 2019;41:699-704.
Pignolo RJ, Baujat G, Brown MA, et al. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes. Orphanet J Rare Dis. 2019;14:98.
Pignolo RJ, Baujat G, Brown MA, et al. The natural history of fibrodysplasia ossificans progressiva: a prospective, global 36-month study. Genet Med. 2022;24(12):2422-2433.
Kaplan FS, Pignolo RJ, Al Mukaddam MM, et al. Hard targets for a second skeleton: therapeutic horizons for fibrodysplasia ossificans progressiva (FOP). Expert Opin Orphan Drugs. 2017;5:291-294.
Kaplan FS, Al Mukaddam M, Baujat G, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP. 2019;1:1-111.
Hind M, Stinchcombe S. Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema. Curr Opin Investig Drugs. 2009;10:1243-1250.
Koyama E, Golden EB, Kirsch T, et al. Retinoid signaling is required for chondrocyte maturation and endochondral bone formation during limb skeletogenesis. Dev Biol. 1999;208:375-391.
Williams JA, Kondo N, Okabe T, et al. Retinoic acid receptors are required for skeletal growth, matrix homeostasis and growth plate function in postnatal mouse. Dev Biol. 2009;328:315-327.
Shimono K, Tung WE, Macolino C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med. 2011;17:454-460.
Weston AD, Chandraratna RA, Torchia J, et al. Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. J Cell Biol. 2002;158:39-51.
Hoffman LM, Garcha K, Karamboulas K, et al. BMP action in skeletogenesis involves attenuation of retinoid signaling. J Cell Biol. 2006;174:101-113.
Pacifici M. Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial. Bone. 2018;109:267-275.
Chakkalakal SA, Uchibe K, Convente MR, et al. Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) fibrodysplasia ossificans progressiva (FOP) mutation. J Bone Miner Res. 2016;31:1666-1675.
Pignolo RJ, Baujat G, Hsiao EC, et al. Palovarotene for fibrodysplasia ossificans progressiva (FOP): results of a randomized, placebo-controlled, double-blind phase 2 trial. J Bone Miner Res. 2022;37:1891-1902.
ClinicalTrials.gov. An open-label extension study of palovarotene treatment in FOP [Internet]. Available at: https://clinicaltrials.gov/ct2/show/NCT02279095 [last accessed: June 8, 2021].
ClinicalTrials.gov. An efficacy and safety study of palovarotene for the treatment of FOP (MOVE) [Internet]. Available at: https://clinicaltrials.gov/ct2/show/NCT03312634 [last accessed: June 8, 2021].
Sanders JO, Qiu X, Lu X, et al. The uniform pattern of growth and skeletal maturation during the human adolescent growth spurt. Sci Rep. 2017;7:1-9.
Hsiao EC, Di Rocco M, Cali A, et al. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br J Clin Pharmacol. 2019;85:1199-1207.
Kaplan FS, Al Mukaddam M, Pignolo RJ. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone. 2017;101:123-128.
Mattera MS, Kaplan FS, Pignolo RJ, et al. Patient-reported physical function outcome measure for adults with fibrodysplasia ossificans progressiva: intelligent test design based on promis item banks. Value Health. 2015;18:A165.
Hays RD, Bjorner JB, Revicki DA, et al. Development of physical and mental health summary scores from the Patient-Reported Outcomes Measurement Information System (PROMIS) global items. Qual Life Res. 2009;18:873-880.
Forrest CB, Bevans KB, Pratiwadi R, et al. Development of the PROMIS® pediatric global health (PGH-7) measure. Qual Life Res. 2014;23:1221-1231.
Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266-1277.
Steineck A, MacKenzie JD, Twist CJ. Premature physeal closure following 13-cis-retinoic acid and prolonged fenretinide administration in neuroblastoma. Pediatr Blood Cancer. 2016;63:2050-2053.
Duvalyan A, Cha A, Goodarzian F, et al. Premature epiphyseal growth plate arrest after isotretinoin therapy for high-risk neuroblastoma: a case series and review of the literature. Pediatr Blood Cancer. 2020;67:e28236.
Ahmed N, Sammons J, Khokher M, et al. Retinoic acid suppresses interleukin 6 production in normal human osteoblasts. Cytokine. 2000;12:289-293.
Keaveny T, Clarke B, Cosman F, et al. Biomechanical computed tomography analysis (BCT) for clinical assessment of osteoporosis. Osteoporos Int. 2020;31:1025-1048.
Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res. 1996;11:984-996.
Adelson R. Compound poisson distributions. J Oper Res Soc. 1966;17:73-75.
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407-2418.
Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122-2130.
Ghosh JK, Delampady M, Samanta T. An introduction to Bayesian analysis: theory and methods. New York: Springer; 2006.
Lewis RJ, Wears RL. An introduction to the Bayesian analysis of clinical trials. Ann Emerg Med. 1993;22:1328-1336.
Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. Redwood City, CA: Stanford University Press; 1959.
Regeneron. Regeneron announces encouraging garetosmab phase 2 results in patients with ultra-rare debilitating bone disease [Internet]. 2020. Available at: https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-encouraging-garetosmab-phase-2-results [last accessed: June 17, 2021].
Pignolo RJ, Baujat G, Brown MA, et al. Greater heterotopic ossification burden is associated with reduced mobility, function, and quality of life in individuals with FOP. J Bone Miner Res. 2021;37:71.
Fritz H, Kennedy D, Fergusson D, et al. Vitamin A and retinoid derivatives for lung cancer: a systematic review and meta analysis. PloS One. 2011;6:e21107.
Vallerand IA, Lewinson RT, Farris MS, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178:76-85.
De Luca F, Uyeda JA, Mericq V, et al. Retinoic acid is a potent regulator of growth plate chondrogenesis. Endocrinology. 2000;141:346-353.
Williams JA, Kane M, Okabe T, et al. Endogenous retinoids in mammalian growth plate cartilage: analysis and roles in matrix homeostasis and turnover. J Biol Chem. 2010;285:36674-36681.
Cave A, Plumptre I, Mellerio JE, et al. The adverse effect profile of acitretin in a pediatric dermatology population − longitudinal cohort study and recommendations for monitoring. J Am Acad Dermatol. 2020;83:1779-1781.
DiGiovanna JJ, Sollitto RB, Abangan DL, et al. Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol. 1995;131:1263-1267.
McMullen EA, McCarron P, Irvine AD, et al. Association between long-term acitretin therapy and osteoporosis: no evidence of increased risk. Clin Exp Dermatol. 2003;28:307-309.
Hoover KB, Miller CG, Galante NC, et al. A double-blind, randomized, phase III, multicenter study in 358 pediatric subjects receiving isotretinoin therapy demonstrates no effect on pediatric bone mineral density. Osteoporos Int. 2015;26:2441-2447.
Leachman SA, Insogna KL, Katz L, et al. Bone densities in patients receiving isotretinoin for cystic acne. Arch Dermatol. 1999;135:961-965.
Singh S, Kidane J, Wentworth KL, et al. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report. BMC Musculoskelet Disord. 2020;21:1-8.
Towler OW, Shore EM, Kaplan FS. Skeletal malformations and developmental arthropathy in individuals who have fibrodysplasia ossificans progressiva. Bone. 2020;130:115116.
Bauer AH, Bonham J, Gutierrez L, et al. Fibrodysplasia ossificans progressiva: a current review of imaging findings. Skeletal Radiol. 2018;47:1043-1050.
DiGiovanna JJ. Isotretinoin effects on bone. J Am Acad Dermatol. 2001;45:S176-S182.
Noyes JJ, Levine MA, Belasco JB, et al. Premature epiphyseal closure of the lower extremities contributing to short stature after cis-retinoic acid therapy in medulloblastoma: a case report. Horm Res Paediatr. 2016;85:69-73.
ClinicalTrials.gov. A rollover study to further evaluate the safety and efficacy of palovarotene capsules in male and female participants aged ≥14 years with fibrodysplasia ossificans progressiva (FOP) who have completed the relevant parent studies (PIVOINE) [Internet]. Available at: https://clinicaltrials.gov/ct2/show/NCT05027802 [Last accessed: 10 October 2022].